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Dear Editor, 
 
Mutations in mitofusin 2 (MFN2) are the most common cause of axonal Charcot Marie 
Tooth disease (CMT2) (Polke; 2011).  Additional features known to occasionally occur 
with MFN2-related disorders are optic atrophy, pyramidal signs, scoliosis and deafness 
(Zuchner, 2006; Feely, 2011; Bombelli, 2014). Cognitive impairment has been reported 
in a small number of patients with MFN2 mutations (Genari, 2011; Tufano, 2015).(PMID 
18946002)  
We report a patient with a c.310C>T; p.R104W mutation in MFN2 with severe cognitive 
involvement. The patient (aged 22) is the youngest daughter of five siblings from 
healthy and unrelated parents of Eastern European origin and is the only affected 
person in her family. She had delayed motor development, walking by three years of 
age. Her neuropathy presented in a length-dependent fashion but with significant 
proximal involvement. She required splints from 4 to 8 years of age, a walker between 
age 8 and 13 years, and has used a wheelchair since 13 years of age. In addition to her 
neuropathy, her language was significantly delayed. She first spoke words at age five to 
six and at age 22, speech was limited to short sentences. She could read simple 
sentences, recite the alphabet, and name basic animals and common objects. 
Orientation was limited to name, age, and place but not time. She could accurately 
count objects dispersed in space and name colors.  She had formal cognitive testing 
at age 14 which reported abilities equivalent to a 3-4 year old in some cognitive 
domains.  
Examination at 22 years of age revealed both proximal and distal wasting and 
weakness in the upper (UL) and lower limbs (LL) with  MRC scores of 5 proximally and 
0 distally in the UL, and 4- proximally and 0 distally in the LL. She was areflexicIt was 
not possible to do a sensory examination. There was evidence of bilateral optic atrophy, 
visual acuities were 6/24 in the right eye and 6/18 on the left.   
A nerve conduction study performed at eight years of age revealed an axonal 
neuropathy. There was a marked reduction of the compound muscle action potentials 
(CMAP) of the median (0.6 mV) and ulnar (0.4 mV) nerves, which had a conduction 
velocity of 35.1 m/s. A MRI scan of the brain at 4 years of age revealed widened 
prepontine cisterns (Figure 1). The p.R104W mutation has previously been reported in 
association with learning difficulties (Del Bo et al., 2008; Genari et al., 2011; Tufano et 
al., 2015).   
We describe a patient with severe global developmental delay, providing additional 
evidence that the p.R104W mutation in MFN2 (unlike other MFN2 mutations) may 
cause cognitive impairment in addition to an axonal neuropathy. The molecular 
mechanisms by which the p.R104W mutation results in cognitive impairment is 
unknown.  
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Figure 1. A sagittal T1 weighted MRI demonstrating wide prepontine cisterns 
